Erlotinib (Tarceva™, OSI-774; Pfizer, Inc.) is an orally-active, targeted inhibitor of the
epidermal growth factor receptor (EGFR/HER1), which is part of a key regulatory pathway in …

7639 Background: Erlotinib is an orally available selective EGFR tyrosine-kinase inhibitor.
Erlotinib is approved for the treatment of patients (p) with advanced or metastatic NSCL that …

Introduction: This phase 2 study was conducted to determine the efficacy and safety of
erlotinib alone and with bortezomib in patients with non-small cell lung cancer (NSCLC) …

Purpose This study investigated whether sequential administration of erlotinib and
chemotherapy improves clinical outcomes versus chemotherapy alone in unselected …

Background We conducted a phase II trial of erlotinib in patients with advanced non-small-
cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations and …

Introduction: Erlotinib improves survival in patients with advanced non-small cell lung cancer
who have been previously treated with systemic chemotherapy. The current trial was …

7504 Background: Poor performance status (PS) NSCLC is an important, under-studied
group of lung cancer patients, affecting 30-40% of patients. We determined the role of …

PURPOSE: The use of erlotinib after gefitinib failure in patients with non-small cell lung
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …

chemotherapy in terms of PFS, main endpoint of the trial, with 9.7 versus 5.2 months,
respectively (HR 0.37, 95% CI 0.25-0.54). ORRs were 58% and 15%, respectively. OS data …

CONTEXT: Erlotinib therapy for non small-cell lung cancer (NSCLC) has mainly been
evaluated in randomized trials. METHOD: OBSTAR was a multicenter, retrospective …